|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
LHGDN |
Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.
|
16757555 |
2006 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Low serum Sex Hormone-Binding Globulin (SHBG) has been proposed as an indicator of the Metabolic Syndrome (MS) and cardiovascular disease in men.
|
20690069 |
2011 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Measurements of SHBG are widely used to predict plasma free testosterone levels in patients suffering from excess androgen exposures, but have broader utility in assessing the risk for endocrine diseases and clinical sequelae of the metabolic syndrome, namely, type 2 diabetes and cardiovascular disease.
|
22531107 |
2012 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Low plasma sex hormone-binding globulin (SHBG) levels in overweight individuals are a biomarker for the metabolic syndrome and are predictive of type 2 diabetes and cardiovascular disease risk.
|
26441241 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, participants with CVD had significantly higher central SBP and AIx@75 compared with those without CVD.
|
29049227 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MRI-derived subclinical HFF is associated with SBP and DBP as well as with hypertension in participants from the general population without history of cardiovascular disease.
|
28253218 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Residing in areas with higher ISA or NTL, or lower greenness, was significantly associated with elevated SBP, DBP, and cPP, and with lower FMD, adjusting for age, BMI, sex, smoking status, and other CVD risk factors.
|
28886599 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In middle-age, SBP in both races identified risk of incident CVD.
|
28199497 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
If SBP was more than 140 mmHg, treatment reduced all-cause and cardiovascular mortality, cardiovascular disease, stroke, myocardial infarction and heart failure.
|
27870655 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this systematically searched meta-analysis was to assess the effects of consuming ≥0.5 or <0.5 servings of total red meat/d on CVD risk factors [blood total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides, ratio of TC to HDL cholesterol (TC:HDL), and systolic and diastolic blood pressures (SBP and DBP, respectively)].
|
27881394 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, we should prioritize not only control of SBP levels but also BPV to reduce CVD events further.
|
28350621 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Distinguishing trajectories allows identification of subgroups at risk of hypertension and cardiovascular disease later in life and in addition can inform the design of targeted interventions to attenuate high SBP and DBP trajectories over time and maintain normal trajectories.
|
28234673 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, for patients with protein-creatinine ratio >500 mg/g (albumin-creatinine ratio > 300 mg/g), with or without diabetes, lower SBP target should be proposed for renal protection aiming SBP < 130 mmHg as recommended by KDIGO guidelines.In patients at low or intermediate risk, without cardiovascular disease, SBP should start to be treated when SBP is above 140 mmHg, and when treated, target BP should be less than 140 mmHg as reported by HOPE-3 trial.
|
27722961 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, both ambulatory SBP and DBP were independently associated with CVD.
|
28422891 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In a prospective cohort study, we evaluated baseline levels of SHBG, T, and DHT using liquid chromatography-tandem mass spectrometry among 852 men free of diabetes and cardiovascular disease in the Cardiovascular Health Study in 1994.
|
27732332 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings support a SBP treatment target of 140 mmHg and suspect no risk reduction attenuation on CVD for lower SBP targets (<120 or <130 mmHg) for most patients with uncomplicated T2DM.
|
29592967 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Total estradiol (E<sub>2</sub>), total testosterone (TT), androstenedione (AD), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG) and NT-proBNP were assessed in 4112 postmenopausal women free of cardiovascular diseases from the prospective population-based Rotterdam Study.
|
29551255 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Investigate relations of mass spectrometry-assessed estrone (E1), E2, and T and SHBG and subclinical CVD in women.
|
29788255 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Adjusted cubic spline analysis showed significant nonlinear but different association between SBP and CVD mortality among diabetes mellitus (U-shaped) and NON-DM (J-shaped).
|
28800042 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Background Both sex hormone-binding globulin and central obesity have been found to be associated with metabolic and cardiovascular diseases.
|
29770358 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Linear, logistic, and Cox regression models assessed the association of top quartiles (P75) of serum testosterone, free androgen index (FAI), dehydroepiandrosterone, and androstenedione and sex hormone-binding globulin with coronary artery calcium, carotid intima-media thickness (IMT), pulse wave velocity, peripheral artery disease, and incidence of coronary heart disease (CHD), stroke, and CVD.
|
29408955 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To explore the association between systolic and diastolic blood pressure (SBP and DBP respectively) and pulse pressure (PP) with cardiovascular disease (CVD) and mortality events among Iranian patients with prevalent CKD.
|
30111315 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AGHD = adult growth hormone deficiency; ASCVD = atherosclerotic cardiovascular disease; AUROC = area under the receiver operating characteristic curve; BMI = body mass index; CVAI = Chinese visceral adiposity index; CVD = cardiovascular disease; DBP = diastolic blood pressure; GH = growth hormone; GHRT = GH replacement therapy; HDL-C = high-density lipoprotein cholesterol; IGF-1 = insulin like factor-1; IGFBP-3 = insulin like factor binding protein-3; IR = insulin resistance; LAP = lipid accumulation product; MS = metabolic syndrome; SBP = systolic blood pressure; TC = total cholesterol; TG = triglycerides; VAI = visceral adiposity index; WC = waist circumference; WHR = waist-to-hip ratio.
|
29144802 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, CR decreased blood pressure (SBP -8 ± 3 mmHg, P = 0.005; DBP -6 ± 2 mmHg, P < 0.001), total cholesterol (-13.6 ± 5.3 mg/dl, P = 0.001), and LDL-cholesterol (-12.9 ± 4.4 mg/dl, P = 0.005), and the 10-yr risk of CVD-disease was reduced by 30%.
|
29351490 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The association between lower SBP and lesser risk of CVD may instead suggest a beneficial effect of lower SBP.
|
31188164 |
2019 |